<?xml version="1.0" encoding="UTF-8"?>

<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/">
	<channel>
		<title>Pesquisa | Influenza A (H1N1): id:mdl-22000086</title>
		<link>http://pesquisa.bvsalud.org:80/h1n1/index.php</link>
		<description>A Biblioteca Virtual em Saúde é visualizada como a base distribuída do conhecimento científico e técnico em saúde registrado, organizado e armazenado em formato eletrônico nos países da Região, acessíveis de forma universal na Internet de modo compatível com as bases internacionais. </description>

				
					
					
			<item>
				<title>Reverse-transcription polymerase chain reaction/pyrosequencing to characterize neuraminidase H275 residue of influenza A 2009 H1N1 virus for rapid and specific detection of the viral oseltamivir resistance marker in a clinical laboratory.</title>
				<author><![CDATA[Bao JR; Huard TK; Piscitelli AE; Tummala PR; Aleemi VE; Coon SL; Master RN; Lewinski MA; Clark RB]]></author>

									<link>http://dx.doi.org/10.1016/j.diagmicrobio.2011.09.003</link>				
							    
			    
             <description>
                 <![CDATA[
                 		MEDLINE	
                     Autor(es): Bao JR; Huard TK; Piscitelli AE; Tummala PR; Aleemi VE; Coon SL; Master RN; Lewinski MA; Clark RB
                     <p>Fonte: Diagn Microbiol Infect Dis;71(4): 396-402, 2011 Dec. </p>
                                              <p>Pandemic 2009 H1N1 is normally susceptible to oseltamivir, but variants harboring the H275Y (CAC â TAC) mutation exhibit resistance. We describe the use of a combined reverse-transcription polymerase chain reaction (RT-PCR)/pyrosequencing approach to identify the H275 residue. A total of 223 specimens were tested with this method: 216 randomly selected clinical specimens positive for 2009 H1N1 and 7 cell-culture supernatants from the Centers for Disease Control and Prevention (CDC; 4 resistant, 3 susceptible 2009 H1N1 strains). The assay detected H275Y in 1 clinical respiratory sample (0.5%) and all 4 oseltamivir-resistant strains from the CDC; the remaining 215 clinical and 3 susceptible CDC specimens were wild-type. Sanger sequencing confirmed the results for 50 of 50 selected isolates. The RT-PCR/pyrosequencing method was highly specific, producing no amplicons or valid sequences from samples containing non-H1N1 viruses or bacteria. Our findings suggest that this method provides a rapid tool for H275Y detection, with high sensitivity and potential benefit for patient care.</p>
                                          <p>
                         Assunto(s):
                         Antivirais/farmacologia; Farmacorresistência Viral; Vírus da Influenza A Subtipo H1N1/genética; Neuraminidase/genética; Oseltamivir/farmacologia; Reação em Cadeia da Polimerase Via Transcriptase Reversa/métodos; Análise de Sequência de DNA/métodos; Proteínas Virais/genética; Adulto; Humanos; Vírus da Influenza A Subtipo H1N1/isolamento &amp; purificação; Influenza Humana/virologia; Masculino; Testes de Sensibilidade Microbiana/métodos; Mutação de Sentido Incorreto; Sensibilidade e Especificidade
                     </p>
                 ]]>
             </description>

			</item>
			</channel>
</rss>